Carbamazepine Stevens-Johnson HLA Screening

Assess carbamazepine Stevens-Johnson syndrome and toxic epidermal necrolysis risk using HLA-B*1502 and HLA-A*3101 genotyping before prescribing.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess carbamazepine Stevens-Johnson syndrome and toxic epidermal necrolysis risk using HLA-B*1502 and HLA-A*3101 genotyping before prescribing

Each component has a specific meaning:

  • HLA-B*1502 — The hla-b*1502 recorded for the scenario being assessed.
  • HLA-A*3101 genotyping before prescribing — The hla-a*3101 genotyping before prescribing recorded for the scenario being assessed.

Note: Interpret the cbz sjs hla screening result against the thresholds and context described above.

How to Use

Enter the HLA-B*1502, HLA-A*3101 genotyping before prescribing for the scenario you are assessing. Assess carbamazepine Stevens-Johnson syndrome and toxic epidermal necrolysis risk using HLA-B*1502 and HLA-A*3101 genotyping before prescribing. Use the cbz sjs hla screening result to inform your calculation.

Frequently Asked Questions